Orphan drug designation granted to Qutenza for postherpetic neuralgia - MPR

Links shared publicly online about this topic.

1,998
total visits

Orphan drug designation granted to Qutenza for postherpetic neuralgia - MPR

NeurogesX announced that the FDA has granted orphan drug designation for its drug candidate, Qutenza (capsaicin) dermal patch, for the management of neuropathic pain in patients with postherpetic neuralgia (PHN).

View full resource at empr.com

Tags: Pain, Neuropathic Pain, Drug, FDA

Most Recently Shared on June 2, 2009 at 6:11 pm By:

MPR

MPR News: Orphan drug designation granted to Qutenza for postherpetic neuralgia: NeurogesX announced th.. http://tinyurl.com/qv2jp5

3 years ago...

Retweet

Favorite

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

news-medical.net — “EpiCept Corporation announced today that EpiCeptTM NP-1 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of post-herpetic neuralgia (PHN). NP-1 is a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies.” View full resource at news-medical.net